Previous 10 | Next 10 |
2023-08-15 12:49:49 ET More on Pharvaris Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate Pharvaris adds 58% on positive data from mid-stage hereditary angioedema trial P...
2023-08-14 09:31:04 ET Summary BioCryst's Q2 2023 earnings report showed a 25.9% YOY revenue rise, mainly from Orladeyo, with a net loss of $75.3M. Concerns arise due to declining liquidity, significant debt, and competition; however, Orladeyo shows promising growth potential. ...
2023-08-03 14:30:28 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q2 2023 Earnings Call Aug 03, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q2 2023 Ear...
2023-08-03 12:55:04 ET BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Conference Call August 03, 2023, 08:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Ch...
2023-08-03 07:06:03 ET BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q2 Non-GAAP EPS of -$0.24 misses by $0.03 . Revenue of $82.49M (+25.9% Y/Y) beats by $1.06M . Cash, cash equivalents, restricted cash and investments totaled $415.7 million at June ...
— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS of ($0.40), non-GAAP EPS o...
2023-08-02 14:21:09 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $81.43M (+24.3% Y/Y). Over the last 1 y...
2023-07-25 18:21:53 ET Gainers: PacWest Bancorp ( PACW ) +38% . PacWest Bancorp ( PACWP ) +15% . Tenable Holdings ( TENB ) +9% . DISH Network ( DISH ) +7% . WW International ( WW ) +7% . Losers: Encore Wire ( ...
RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, August 3, 2023. BioCryst management will host a conference call and webcas...
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO ® (berotralstat) in Turkey. “We continue ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast ...
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...